EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma - OncLive
Evaxion presented translational data at SITC 2026 from its phase 2 trial (NCT05309421) of EVX-01, an AI-designed personalized peptide vaccine, plus pembrolizumab in advanced melanoma: in the single-arm study (n=16, predominantly stage IV), ORR was 75% with 25% complete responses by RECIST 1.1, and 89% of 118 vaccine neoantigens induced T-cell responses, with sustained effector memory T-cell enrichment. The data tie the company's neoantigen-selection platform to both immunologic activity and durable responses in a late-line setting. The cohort is small and uncontrolled, but the paired immune-correlate package is the kind of evidence partners and regulators look for as the combination moves forward.